Latest News From Pharmachem
Amgen receives FDA Breakthrough Therapy Designation for investigational BiTE antibody blinatumomab in acute lymphoblastic leukemia
02 July, 2014
Amgen (NASDAQ:AMGN) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to investigational bispecific T cell engager (BiTE) antibody blinatumomab, for adults with Philadelphia-negative (Ph-) relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL), a rapidly progressing cancer of the blood and bone marrow(1).
11 July, 2014
Pfizer has confirmed that a change in work practices and an upsurge in workload means it is not going to press ahead with 100 of the 130 redundancies it had flagged one of its Cork plants two years ago.
16 July, 2014
Novartis announced that its eye care division Alcon has entered into an agreement with a division of Google Inc. to in-license its "smart lens" technology for all ocular medical uses. The agreement with Google[x], a team within Google that is devoted to finding new solutions to big global problems, provides Alcon with the opportunity to develop and commercialize Google's "smart lens" technology with the potential to transform eye care and further enhance Alcon's pipeline and global leadership in contact lenses and intraocular lenses. The transaction remains subject to anti-trust approvals.
23 July, 2014
Merck, a leading company for high-tech products in the pharmaceutical and chemical sectors, today reiterated its commitment to investments in the Chinese market, strengthening a major pillar of its emerging markets growth strategy.
30 July, 2014
Microorganisms like bacteria and fungi can evade treatment by acquiring mutations in the genes targeted by antibiotics or antifungal drugs. These permanent mutations were once thought to be the only way for drug-resistant strains to evolve. Now a new study has shown that microorganisms can use a temporary silencing of drug targets - known as epimutations - to gain the benefits of drug resistance without the commitment.